Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Milos D Miljkovic, Adam S. Asch, Gregory Orloff, Ralph Boccia, Jesús G Berdeja, Fevzi Altuntas, Stefan O. Ciurea, James F Howard, Jr., Tuan Vu, Bennett Myers, Nizar Chahin, Tahseen Mozaffar, Christopher M Jewell, Metin Kurtoglu

Blood (2024) 144 (Supplement 1): 2080.

https://doi.org/10.1182/blood-2024-203585

Published: 2024

Journal Articles

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

Jonathan W. Friedberg, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Adrija Mamidipalli, Jingmin Liu, Alev Akyol, Christopher A. Yasenchak

Blood (2024) 143 (9): 786–795.

https://doi.org/10.1182/blood.2022019536

Published: 2024

Includes: Supplemental data

Journal Articles

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone

James R Berenson, Andrea Limon, Stephanie Rice, Tahmineh Safaie, Ralph Boccia, Honghao Yang, Mehdi M. Moezi, Stephen Lim, Gary Schwartz, Shahrooz Eshaghian, Matthew Brobeck, Regina Swift, Benjamin M. Eades, Sean Bujarski, Yohana Sebhat, Rudra Ray, Susanna Kim, Robert Allen Vescio

Blood (2023) 142 (Supplement 1): 4753.

https://doi.org/10.1182/blood-2023-180287

Published: 2023

Journal Articles

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Christopher Yasenchak, Rodolfo Bordoni, Dipti Patel-Donnelly, Timothy Larson, Jerome Goldschmidt, Ralph Boccia, Vivian J. M. Cline, Shweta Jain, Jingmin Liu, Joseph Thaddeus Beck

Blood (2023) 142 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2023-190260

Published: 2023

Journal Articles

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Ralph Boccia, Hong Xiao, Dimana Miteva, Min Che, Tao Gu, Ali McBride, Mrudula B. Glassberg, Aylin Yucel

Blood (2023) 142 (Supplement 1): 7411.

https://doi.org/10.1182/blood-2023-173360

Published: 2023

Journal Articles

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, Daisy Martinez, Tahmineh Safaie, Ralph Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Gary Edward Schwartz, Shahrooz Eshaghian, Regina Swift, Benjamin Eades, Sean Elliott Bujarski, Bernard Sean Regidor, Clara Kim, Susanna Kim, Robert Vescio

Blood (2022) 140 (Supplement 1): 12610–12611.

https://doi.org/10.1182/blood-2022-163872

Published: 2022

Journal Articles

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis

Chris LaVallee, M.S, Patrick Cronin, M.A, Isha Bansal, M.S, Jackie Kwong, PhD PharmD, Ralph Boccia, MD

Blood (2019) 134 (Supplement_1): 3445.

https://doi.org/10.1182/blood-2019-125793

Published: 2019

Journal Articles

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Ralph Boccia, MD, Michael A. Boxer, MD, Waleed Ghanima, MD PhD, Quentin A. Hill, Michelle Sholzberg, MDBSc,FRCPC,MSc, Michael D. Tarantino, MD, Yuliya Kreychman, PharmD, Robert P. Numerof, PhD, Brian Olender, BA, Leslie Todd, Sandy Tong, MD, Anne-Marie Duliege, MDMS, Nichola Cooper, MD MRCP, James B. Bussel, MD

Blood (2019) 134 (Supplement_1): 1069.

https://doi.org/10.1182/blood-2019-126473

Published: 2019

Journal Articles

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Meletios Dimopoulos, David Siegel, Darrell J. White, Ralph Boccia, Karim S. Iskander, Zhao Yang, Amy S. Kimball, Khalid Mezzi, Heinz Ludwig, Ruben Niesvizky

Blood (2019) 133 (2): 147–155.

https://doi.org/10.1182/blood-2018-06-860015

Published: 2019

Includes: Supplemental data

Journal Articles

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Shaji K. Kumar, MD, Alan Fu, PhD MPH, Khalid Mezzi, Megan Braunlin, Christopher Kim, PhD, Karim Iskander, Ruben Niesvizky, MD, Sundar Jagannath, MD, Ralph Boccia, MD, Noopur Raje, MD

Blood (2018) 132 (Supplement 1): 3253.

https://doi.org/10.1182/blood-2018-99-113519

Published: 2018

Journal Articles

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

Anne-Marie Duliege, MDMS, Donald M. Arnold, MD MSc, FRCPC, Ralph Boccia, MD, Michael Boxer, MD, Nichola Cooper, MRCP, Quentin A Hill, BSc, MBChB, MRCP, FRCPath, Darla K Liles, MD, Michelle Sholzberg, MDM, MSc, FRCPC, Hany Zayed, PhD, Sandra Tong, MD, James B. Bussel, MD

Blood (2018) 132 (Supplement 1): 736.

https://doi.org/10.1182/blood-2018-99-110482

Published: 2018

Journal Articles

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

Nirmish Shah, Ralph Boccia, Walter K. Kraft, Brandon M. Hardesty, Jincy Paulose, Dram Laine, Das Purkayastha, Savita Nandal, Abdullah Kutlar, MD

Blood (2018) 132 (Supplement 1): 4910.

https://doi.org/10.1182/blood-2018-99-111332

Published: 2018

Journal Articles

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

James R. Berenson, Alan Cartmell, Alberto Bessudo, Roger M. Lyons, Wael Harb, Dimitrios Tzachanis, Richy Agajanian, Ralph Boccia, Morton Coleman, Robert A. Moss, Robert M. Rifkin, Priti Patel, Sandra Dixon, Ying Ou, Janet Anderl, Sanjay Aggarwal, Jesus G. Berdeja

Blood (2016) 127 (26): 3360–3368.

https://doi.org/10.1182/blood-2015-11-683854

Published: 2016

Includes: Supplemental data

Journal Articles

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Deborah Mulford, MD, Scott E. Smith, MD, PhD, FACP, Gail Brown, MD, Lisa Meng, PhD, David P. Steensma, MD, Roger M. Lyons, MD, Ralph Boccia, MD, Mikkael A. Sekeres, MD, MS, Guillermo Garcia-Manero, Ruben A. Mesa, MD

Blood (2011) 118 (21): 2778.

https://doi.org/10.1182/blood.V118.21.2778.2778

Published: 2011

Journal Articles

Iron Deficiency Anemia and Chronic Renal Insufficiency In An Oncology Population

Ralph Boccia, MD, Betsy Lahue, MPH, Robert Hauser, PharmD, PhD, Jessica Dioguardi, RPh

Blood (2010) 116 (21): 5152.

https://doi.org/10.1182/blood.V116.21.5152.5152

Published: 2010

Journal Articles

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Ralph Boccia, MD, David J. Kuter, MD, DPhil, Mathias J. Rummel, MD, PhD, B. Gail Macik, MD, Ingrid Pabinger, MD, Dominik Selleslag, MD, Francesco Rodeghiero, MD, Beng Chong, MBBS, PhD, Xuena Wang, PhD, Richard Lizambri, MD

Blood (2010) 116 (21): 3702.

https://doi.org/10.1182/blood.V116.21.3702.3702

Published: 2010

Journal Articles

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Ian W. Flinn, MD, PhD, Evan Lang, MD, Eric Raefsky, MD, Ralph Boccia, MD, Inés M. Macias-Pérez, PhD, Howard A. Burris, III, MD, John D. Hainsworth, MD

Blood (2010) 116 (21): 4015.

https://doi.org/10.1182/blood.V116.21.4015.4015

Published: 2010

Journal Articles

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

Taimur Sher, MD, Jose Azar, MD, Stephen Spurgeon, MD, John Catalano, MBBS, FRACP, FRCPA, Richard R. Furman, MD, Miles Prince, MD, FRACP, FRCPA, Nancy L. Bartlett, MD, Simon Durrant, MBBS, FRCP, FRCPath, Ralph Boccia, MD, Aisha Masood, MD, Scott Lyman, MS, Jean Cantey-Kiser, William P Sheridan, MB, BS, Asher Chanan-Khan, MD

Blood (2010) 116 (21): 1397.

https://doi.org/10.1182/blood.V116.21.1397.1397

Published: 2010

Journal Articles

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

James R. Berenson, MD, Ori Yellin, MD, Alberto Bessudo, MD, Ralph Boccia, MD, Donald S. Gravenor, MD, Stephen J. Noga, MD, PhD, Robert S Siegel, MD, Regina A. Swift, RN, Michael D Ehrman, MS, Debra Bensen-Kennedy, MD

Blood (2010) 116 (21): 3057.

https://doi.org/10.1182/blood.V116.21.3057.3057

Published: 2010

Journal Articles

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Azra Raza, MD, Naomi Galili, Ph.D., Scott Smith, MD, PhD, FACP, John E. Godwin, MD, MS, Ralph Boccia, MD, Han Myint, MD, Daruka Mahadevan, MD, PhD, Deborah Mulford, MD, Mark Rarick, MD, Mary Ann Allison, MD, Ostap Melnyk, MD, Lisa Meng, Marsha Jones, MD, Gail Brown, MD, Shelby A Young, RN, BSN, Mikkael A. Sekeres, MD, MS

Blood (2010) 116 (21): 2910.

https://doi.org/10.1182/blood.V116.21.2910.2910

Published: 2010

NARROW

Safety and Tolerability of BCMA-Directed mRNA CAR T-Cell Therapy in Multiple Myeloma and Autoimmune Disease

Brentuximab vedotin with dacarbazine or nivolumab as frontline cHL therapy for older patients ineligible for chemotherapy

A Phase 1 Trial Evaluating the Addition of Lenalidomide to Relapsed/Refractory Multiple Myeloma Patients Progressing on Ruxolitinib and Methylprednisolone

Brentuximab Vedotin in Frontline Therapy of Hodgkin Lymphoma in Patients with Significant Comorbidities Ineligible for Standard Chemotherapy (SGN35-015 Part E)

Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Lower-Risk Myelodysplastic Syndromes Who Have Been Treated with Luspatercept

Ruxolitinib and Methylprednisolone for Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Impact of Parenteral Iron Therapy on Hemoglobin Normalization: A Retrospective Analysis

Enhanced Responses to Fostamatinib As Second-Line Therapy and in Persistent Immune Thrombocytopenia (ITP) Patients

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Renal Response in Carfilzomib (K)- Versus Bortezomib (V)-Treated Patients (Pts) with Relapsed or Refractory Multiple Myeloma (RRMM) in the Real-World Practice Setting

Two-Year Safety and Efficacy Outcomes with Fostamatinib in Adult Patients with Immune Thrombocytopenia (ITP): Open-Label Extension to Phase 3 Trial Program

A Multicenter Retrospective Noninterventional Follow-up Study in Patients with Sickle Cell Pain Crisis Who Previously Participated in the Sustain Trial in the United States Successor Study

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

Phase 1 Dose-Ranging Study of Oral Ezatiostat Hydrochloride (Telintra®, TLK199) in Combination with Lenalidomide (Revlimid®) in Patients with Non-Deletion(5q) Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Iron Deficiency Anemia and Chronic Renal Insufficiency In An Oncology Population

The Effects of Romiplostim or Standard of Care (SOC) on Splenectomy and Treatment Failure of Patients Who Had Immune Thrombocytopenia (ITP) for Less Than or Equal to One Year.

Preliminary Results of a Phase II Trial of Panobinostat (LBH589) In Refractory Myelodysplastic Syndromes (MDS) Patients

Forodesine, a Purine Nucleoside Phosphorylase (PNP) Inhibitor, Shows Clinical Activity In a Phase 2 Trial In Patients with Previously Treated Chronic Lymphocytic Leukemia (CLL) – Interim Analysis

An Open-Label Phase 1/2 Trial of Bendamustine Combined with Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma

Phase 2 Randomized Multicenter Study of Extended Dosing Schedules of Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, In Low to Intermediate-1 Risk Myelodysplastic Syndrome (MDS)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only